Exicure, Inc. (XCUR): R&D Expense
$3.29M
Year ended 2025-12-31
$2.03M
Trailing 12 months to 2026-06-30
-45.0%
3-year compound annual growth
-36.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.29M | n/a | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $0 | -100.0% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $1.42M | -92.8% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $19.77M | -59.6% | 2024-06-06, From 2022-01-01 |
| 2021-12-31 | $48.98M | +52.6% | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | $32.09M | +65.9% | 2022-03-25, From 2020-01-01 |
| 2019-12-31 | $19.34M | +37.0% | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | $14.12M | +7.9% | 2020-03-10, From 2018-01-01 |
| 2017-12-31 | $13.08M | n/c | 2019-09-23, From 2017-01-01 |
| 2016-12-31 | $13.66M | n/a | 2018-03-09, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Exicure, Inc. (XCUR) | 2025-12-31 | $3.29M | n/a |
| Abbott Laboratories (ABT) | 2025-12-31 | $2.94B | +3.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $9.95B | -10.8% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $13.34B | +21.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $10.44B | -3.6% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $14.66B | -14.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $1.90M | +11.8% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $15.79B | -12.0% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $1.90M | -7.5% |
Compare XCUR, ABT, BMY, LLY side by side · Screen every company in Pharmaceutical Preparations ↗